Tag: shingles vaccine market forecast

Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.

Shingles Vaccine Market Size And Revenue Outlook Through 2030

The shingles vaccine market has experienced swift expansion in recent years. This market is projected to increase from $5.55 billion in 2025 to $6.37 billion in 2026, achieving a compound annual growth rate (CAGR) of 14.8%. The historical growth was driven by factors such as the limited availability of shingles vaccines, a reliance on live attenuated vaccines, an expanding elderly population, the rising incidence of herpes zoster, and growing awareness regarding the benefits of immunization.

The shingles vaccine market size is set to undergo significant expansion over the next few years, with projections indicating it will reach $10.96 billion in 2030, growing at a compound annual growth rate (CAGR) of 14.5%. This anticipated growth is primarily fueled by the progression of recombinant and subunit vaccine development, the spread of both public and private vaccination drives, the increasing preference for online and retail pharmacy distribution, a rise in government and healthcare programs for elderly immunization, and the integration of digital health monitoring to support vaccination adherence. Noteworthy trends for the forecast period include the growing adoption of recombinant and subunit shingles vaccines, a heightened understanding of shingles prevention among older adults, the expansion of vaccination initiatives through hospital and retail pharmacies, the proliferation of online pharmacies and e-commerce in vaccine distribution, and a strategic emphasis on age-specific immunization for the population aged 50 and over.

Get A Free Sample Report With In-Depth Market Insights:

https://thebusinessresearchcompany.com/sample_request?id=20846479&type=smp&name=Shingles%20Vaccine%20Market%20Report%202026&utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Shingles Vaccine Market Growth Factors Behind Sustained Expansion

The increasing prevalence of vaccination programs is projected to boost the expansion of the shingles vaccine market going forward. Vaccination programs are defined as structured public health initiatives aimed at systematically delivering vaccines to populations to curb the spread of infectious diseases. The rise in these programs is due to growing recognition of preventive healthcare, encouraging more people to get vaccinated to avoid illnesses. These initiatives enhance the uptake of shingles vaccines by elevating public awareness and improving accessibility, making them particularly suitable for older adults and other vulnerable groups. They effectively lower the risk of shingles and associated complications by promoting widespread and timely immunization, thereby contributing to better overall community health. For instance, in July 2025, the World Health Organization, a Switzerland-based intergovernmental body, noted that the coverage for the first dose of the human papillomavirus (HPV) vaccine in girls increased from 27% in 2023 to 31% in 2024. Consequently, the growing number of vaccination programs is a key driver for the growth of the shingles vaccine market.

Shingles Vaccine Market Segment Landscape: Which Areas Lead Development?

The shingles vaccine market covered in this report is segmented –

1) By Vaccine Type: Live Attenuated Vaccine, Recombinant Vaccine, Subunit Vaccine

2) By Product: Shingrix, Zostavax, Skyzoster

3) By Age Group: 50-59 Years, 60-69 Years, 70 Years And Above

4) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies

5) By End User: Hospitals, Clinics, Pharmacies

Subsegments:

1) By Live Attenuated Vaccine: Virus Strain A, Virus Strain B, Virus Strain C

2) By Recombinant Vaccine: Recombinant Protein Vaccine, Recombinant Vector Vaccine, Recombinant Deoxyribonucleic Acid Vaccine

3) By Subunit Vaccine: Protein Subunit Vaccine, Conjugate Subunit Vaccine

Shingles Vaccine Market Industry Trends Fueling Future Revenue Growth

Leading companies operating within the shingles vaccine market are concentrating on developing innovative vaccine formulations, such as recombinant adjuvanted vaccines, aiming to enhance immune response and provide sustained protection against shingles. These recombinant adjuvanted vaccines utilize laboratory-produced viral proteins combined with substances known as adjuvants to boost the body’s immune system, leading to improved and longer-lasting defense. For instance, in April 2023, GlaxoSmithKline Pharmaceuticals Ltd., an India-based pharmaceutical company, launched Shingrix, a vaccine targeting shingles. Shingrix is a non-live, recombinant adjuvanted subunit vaccine administered intramuscularly in two doses for adults aged 50 and above, specifically designed to prevent shingles (herpes zoster) and its related complication, post-herpetic neuralgia. This highly effective vaccine offers over 90% protection against shingles, establishing strong and sustained immunity for at least 10 years, even in older adults and individuals with compromised immune systems.

Shingles Vaccine Market Industry Leaders And Competitive Landscape

Major companies operating in the shingles vaccine market are Merck & Co. Inc., GSK plc, SK bioscience, Pfizer Inc, GeneOne Life Science, Curevo Inc, Novavax Inc

View The Full Shingles Vaccine Market Report:

https://thebusinessresearchcompany.com/report/shingles-vaccine-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Shingles Vaccine Market Geographic Analysis: Where Is Demand Accelerating Fastest?

North America was the largest region in the shingles vaccine market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the shingles vaccine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Reach Out To Our Team:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.

Shingles Vaccine Market Size Outlook: How Fast Will Revenue Grow Through 2030?

The shingles vaccine market has experienced significant expansion over the past several years, with projections showing an increase from $5.55 billion in 2025 to $6.37 billion in 2026, reflecting a compound annual growth rate (CAGR) of 14.8%. This historical growth has been driven by factors such as the constrained supply of shingles vaccines, a dependence on live attenuated formulations, the expanding elderly demographic, a higher prevalence of herpes zoster cases, and a growing public understanding of the advantages associated with immunization.

The shingles vaccine market is projected to experience significant expansion over the coming years, with an anticipated value of $10.96 billion by 2030, driven by a compound annual growth rate (CAGR) of 14.5%. This forecasted growth is fueled by the development of recombinant and subunit vaccines, the broadening of both public and private vaccination initiatives, a growing reliance on online and retail pharmacy channels for distribution, increased government and healthcare efforts aimed at immunizing the elderly, and the incorporation of digital health monitoring to improve vaccine adherence. Key trends shaping this period include a higher uptake of recombinant and subunit shingles vaccines, greater awareness about shingles prevention among older adults, the expansion of vaccination programs via hospitals and retail pharmacies, the rise of online pharmacies and e-commerce for vaccine distribution, and a targeted focus on age-specific immunization strategies for individuals aged 50 and older.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=27413&type=smp&utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Shingles Vaccine Market Industry Drivers: What Is Driving Revenue Growth?

The growth of the shingles vaccine market is anticipated to be driven forward by the rising number of vaccination initiatives. These initiatives are organized public health efforts aimed at the systematic delivery of vaccines to populations to curb the spread of infectious diseases. A growing focus on preventive healthcare, which encourages more individuals to seek vaccination as a means of avoiding illness, has led to an increase in the number of such programs. By boosting public awareness and improving accessibility, vaccination initiatives facilitate the uptake of the shingles vaccine, particularly benefiting older adults and those at higher risk. Through the encouragement of widespread and timely immunization, they help lower the incidence of shingles and its associated complications, thereby enhancing community health. In July 2025, for example, the World Health Organization—a Switzerland-based intergovernmental body—reported that global coverage for the first dose of the human papillomavirus (HPV) vaccine among girls rose from 27% in 2023 to 31% in 2024. Consequently, the expansion of vaccination programs is propelling the shingles vaccine market forward.

Shingles Vaccine Market Segment Outlook: Which Categories Are Expanding The Fastest?

The shingles vaccine market covered in this report is segmented –

1) By Vaccine Type: Live Attenuated Vaccine, Recombinant Vaccine, Subunit Vaccine

2) By Product: Shingrix, Zostavax, Skyzoster

3) By Age Group: 50-59 Years, 60-69 Years, 70 Years And Above

4) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies

5) By End User: Hospitals, Clinics, Pharmacies

Subsegments:

1) By Live Attenuated Vaccine: Virus Strain A, Virus Strain B, Virus Strain C

2) By Recombinant Vaccine: Recombinant Protein Vaccine, Recombinant Vector Vaccine, Recombinant Deoxyribonucleic Acid Vaccine

3) By Subunit Vaccine: Protein Subunit Vaccine, Conjugate Subunit Vaccine

Shingles Vaccine Market Growth Trends: What Is Influencing The Future Outlook?

Key players in the shingles vaccine market are concentrating on the creation of advanced vaccine formulations, particularly recombinant adjuvanted types, aimed at amplifying immune responses and delivering durable protection against shingles. These vaccines are produced using lab-generated viral proteins paired with adjuvants—substances that stimulate a stronger and more prolonged immune defense. A notable example occurred in April 2023, when GlaxoSmithKline Pharmaceuticals Ltd., a pharmaceutical firm based in India, introduced Shingrix, a shingles vaccine. Administered as two intramuscular doses to individuals aged 50 and over, Shingrix is a non-live, recombinant adjuvanted subunit vaccine specifically formulated to prevent shingles (herpes zoster) and its associated complication, post-herpetic neuralgia. Achieving over 90% efficacy, this vaccine ensures robust and enduring immunity that persists for at least a decade, proving effective for both older adults and those with compromised immune systems.

Shingles Vaccine Market Key Companies And Competitive Benchmarking

Major companies operating in the shingles vaccine market are Merck & Co. Inc., GSK plc, SK bioscience, Pfizer Inc, GeneOne Life Science, Curevo Inc, Novavax Inc

Access The Complete Shingles Vaccine Market Report:

https://www.thebusinessresearchcompany.com/report/shingles-vaccine-global-market-report?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Shingles Vaccine Market Leading Geography: Which Region Generates The Most Revenue?

North America was the largest region in the shingles vaccine market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the shingles vaccine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.

Shingles Vaccine Market Size Outlook: How Fast Will Revenue Grow Through 2030?

The shingles vaccine market has experienced significant expansion over the past several years, with projections showing an increase from $5.55 billion in 2025 to $6.37 billion in 2026, reflecting a compound annual growth rate (CAGR) of 14.8%. This historical growth has been driven by factors such as the constrained supply of shingles vaccines, a dependence on live attenuated formulations, the expanding elderly demographic, a higher prevalence of herpes zoster cases, and a growing public understanding of the advantages associated with immunization.

The shingles vaccine market is projected to experience significant expansion over the coming years, with an anticipated value of $10.96 billion by 2030, driven by a compound annual growth rate (CAGR) of 14.5%. This forecasted growth is fueled by the development of recombinant and subunit vaccines, the broadening of both public and private vaccination initiatives, a growing reliance on online and retail pharmacy channels for distribution, increased government and healthcare efforts aimed at immunizing the elderly, and the incorporation of digital health monitoring to improve vaccine adherence. Key trends shaping this period include a higher uptake of recombinant and subunit shingles vaccines, greater awareness about shingles prevention among older adults, the expansion of vaccination programs via hospitals and retail pharmacies, the rise of online pharmacies and e-commerce for vaccine distribution, and a targeted focus on age-specific immunization strategies for individuals aged 50 and older.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=27413&type=smp&utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Shingles Vaccine Market Industry Drivers: What Is Driving Revenue Growth?

The growth of the shingles vaccine market is anticipated to be driven forward by the rising number of vaccination initiatives. These initiatives are organized public health efforts aimed at the systematic delivery of vaccines to populations to curb the spread of infectious diseases. A growing focus on preventive healthcare, which encourages more individuals to seek vaccination as a means of avoiding illness, has led to an increase in the number of such programs. By boosting public awareness and improving accessibility, vaccination initiatives facilitate the uptake of the shingles vaccine, particularly benefiting older adults and those at higher risk. Through the encouragement of widespread and timely immunization, they help lower the incidence of shingles and its associated complications, thereby enhancing community health. In July 2025, for example, the World Health Organization—a Switzerland-based intergovernmental body—reported that global coverage for the first dose of the human papillomavirus (HPV) vaccine among girls rose from 27% in 2023 to 31% in 2024. Consequently, the expansion of vaccination programs is propelling the shingles vaccine market forward.

Shingles Vaccine Market Segment Outlook: Which Categories Are Expanding The Fastest?

The shingles vaccine market covered in this report is segmented –

1) By Vaccine Type: Live Attenuated Vaccine, Recombinant Vaccine, Subunit Vaccine

2) By Product: Shingrix, Zostavax, Skyzoster

3) By Age Group: 50-59 Years, 60-69 Years, 70 Years And Above

4) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies

5) By End User: Hospitals, Clinics, Pharmacies

Subsegments:

1) By Live Attenuated Vaccine: Virus Strain A, Virus Strain B, Virus Strain C

2) By Recombinant Vaccine: Recombinant Protein Vaccine, Recombinant Vector Vaccine, Recombinant Deoxyribonucleic Acid Vaccine

3) By Subunit Vaccine: Protein Subunit Vaccine, Conjugate Subunit Vaccine

Shingles Vaccine Market Growth Trends: What Is Influencing The Future Outlook?

Key players in the shingles vaccine market are concentrating on the creation of advanced vaccine formulations, particularly recombinant adjuvanted types, aimed at amplifying immune responses and delivering durable protection against shingles. These vaccines are produced using lab-generated viral proteins paired with adjuvants—substances that stimulate a stronger and more prolonged immune defense. A notable example occurred in April 2023, when GlaxoSmithKline Pharmaceuticals Ltd., a pharmaceutical firm based in India, introduced Shingrix, a shingles vaccine. Administered as two intramuscular doses to individuals aged 50 and over, Shingrix is a non-live, recombinant adjuvanted subunit vaccine specifically formulated to prevent shingles (herpes zoster) and its associated complication, post-herpetic neuralgia. Achieving over 90% efficacy, this vaccine ensures robust and enduring immunity that persists for at least a decade, proving effective for both older adults and those with compromised immune systems.

Shingles Vaccine Market Key Companies And Competitive Benchmarking

Major companies operating in the shingles vaccine market are Merck & Co. Inc., GSK plc, SK bioscience, Pfizer Inc, GeneOne Life Science, Curevo Inc, Novavax Inc

Access The Complete Shingles Vaccine Market Report:

https://www.thebusinessresearchcompany.com/report/shingles-vaccine-global-market-report?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Shingles Vaccine Market Leading Geography: Which Region Generates The Most Revenue?

North America was the largest region in the shingles vaccine market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the shingles vaccine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

What Increase In Market Value Is Predicted For The Shingles Vaccine Market During The 2026–2030 Period?

The market for shingles vaccines has experienced significant expansion recently. Projections indicate its value will escalate from $5.55 billion in 2025 to $6.37 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 14.8%. Historically, this expansion was driven by factors such as the restricted supply of shingles vaccines, a dependence on live attenuated versions, the expanding demographic of older individuals, a rise in herpes zoster cases, and enhanced understanding of the advantages of immunization.

The shingles vaccine market is set for significant expansion over the next few years. It is forecast to grow to $10.96 billion in 2030, driven by a compound annual growth rate (CAGR) of 14.5%. This projected growth can be attributed to several factors, including the continuous development of recombinant and subunit vaccines, the wider reach of public and private vaccination campaigns, the increasing utilization of online and retail pharmacy distribution channels, a rise in government and healthcare initiatives focused on immunizing the elderly, and the integration of digital health monitoring to improve vaccination adherence. Prominent trends expected in this forecast period encompass the growing adoption of recombinant and subunit shingles vaccines, enhanced awareness of shingles prevention among older adults, the expansion of vaccination programs via hospital and retail pharmacies, an increase in online pharmacies and e-commerce for vaccine distribution, and a strategic emphasis on age-specific immunization approaches for individuals aged 50 and above.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=27413&type=smp

What Core Drivers Are Transforming The Shingles Vaccine Market?

The shingles vaccine market is anticipated to expand due to the rising number of vaccination programs. These initiatives are structured public health efforts aimed at systematically vaccinating communities to prevent the transmission of infectious illnesses. An uptick in such programs stems from heightened awareness regarding preventive healthcare, prompting more individuals to seek vaccination against diseases. They boost the uptake of the shingles vaccine through greater public understanding and availability, making them particularly suitable for older adults and high-risk demographics. By advocating for prompt and widespread immunization, these programs mitigate the risk of shingles and associated complications, thereby enhancing general community health. For example, data from July 2025, provided by the World Health Organization, a Switzerland-based Intergovernmental organization, shows that the coverage for the first dose of human papillomavirus (HPV) vaccine among girls grew from 27% in 2023 to 31% in 2024. Consequently, the expanding volume of vaccination programs is a key factor driving the growth of the shingles vaccine market.

What Segment Categories Are Evaluated In The Shingles Vaccine Market Study?

The shingles vaccine market covered in this report is segmented –

1) By Vaccine Type: Live Attenuated Vaccine, Recombinant Vaccine, Subunit Vaccine

2) By Product: Shingrix, Zostavax, Skyzoster

3) By Age Group: 50-59 Years, 60-69 Years, 70 Years And Above

4) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies

5) By End User: Hospitals, Clinics, Pharmacies

Subsegments:

1) By Live Attenuated Vaccine: Virus Strain A, Virus Strain B, Virus Strain C

2) By Recombinant Vaccine: Recombinant Protein Vaccine, Recombinant Vector Vaccine, Recombinant Deoxyribonucleic Acid Vaccine

3) By Subunit Vaccine: Protein Subunit Vaccine, Conjugate Subunit Vaccine

What Trends Are Impacting The Shingles Vaccine Market?

Leading companies in the shingles vaccine market are concentrating on developing innovative vaccine formulations, such as recombinant adjuvanted vaccines, to improve immune response and offer long-lasting protection against shingles. These recombinant adjuvanted vaccines utilize laboratory-produced viral proteins combined with substances known as adjuvants to boost the body’s immune response for enhanced and more prolonged protection. For instance, in April 2023, GlaxoSmithKline Pharmaceuticals Ltd., an India-based pharmaceutical company, introduced Shingrix, a shingles vaccine. Shingrix is an inactivated, recombinant adjuvanted subunit vaccine administered intramuscularly in two doses for adults aged 50 and above, designed to prevent shingles (herpes zoster) and its associated complication, post-herpetic neuralgia. This highly effective vaccine provides over 90% protection against shingles, with robust and sustained immunity lasting at least 10 years, even in older adults and immunocompromised individuals.

Which Organizations Are Operating Within The Shingles Vaccine Market?

Major companies operating in the shingles vaccine market are Merck & Co. Inc., GSK plc, SK bioscience, Pfizer Inc, GeneOne Life Science, Curevo Inc, Novavax Inc

Access The Complete Shingles Vaccine Market Report:

https://www.thebusinessresearchcompany.com/report/shingles-vaccine-global-market-report

Which Region Contributes The Most To The Shingles Vaccine Market?

North America was the largest region in the shingles vaccine market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the shingles vaccine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Shingles Vaccine Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=27413&type=smp

Browse Through More Reports Similar to the Global Shingles Vaccine Market 2026, By The Business Research Company

Construction Market Report 2026

https://www.thebusinessresearchcompany.com/report/construction-global-market-report

Folding Furniture Market Report 2026

https://www.thebusinessresearchcompany.com/report/folding-furniture-global-market-report

Foldable Houses Market Report 2026

https://www.thebusinessresearchcompany.com/report/foldable-houses-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Is The Estimated Market Size Of The Shingles Vaccine Market In 2026, And How Will Its Value Evolve By 2030?

The shingles vaccine market size has witnessed rapid growth in recent years. It is anticipated to increase from $5.55 billion in 2025 to $6.37 billion in 2026, driven by a compound annual growth rate (CAGR) of 14.8%. Historically, this expansion has been primarily due to factors such as the limited availability of shingles vaccines, the reliance on live attenuated vaccines, a growing elderly population, the increasing incidence of herpes zoster, and a rising awareness of the benefits of immunization.

The shingles vaccine market is projected to experience substantial expansion in the coming years, with expectations to reach $10.96 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 14.5%. This projected increase is primarily driven by the advancement of recombinant and subunit vaccines, the broadening scope of public and private vaccination efforts, the growing preference for online and retail pharmacy distribution channels, intensified government and healthcare initiatives to immunize the elderly, and the incorporation of digital health monitoring to ensure vaccination compliance. Key developments expected during this period involve a surge in the uptake of recombinant and subunit shingles vaccines, heightened public awareness regarding shingles prevention among older adults, an increase in vaccination program availability through hospitals and retail pharmacies, the expansion of online pharmacies and e-commerce for vaccine distribution, and a strategic emphasis on immunization plans tailored for the population aged 50 and above.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=27413&type=smp

Which Drivers Are Supporting The Shingles Vaccine Market Growth?

A growing number of vaccination programs is anticipated to propel the expansion of the shingles vaccine market in the future. These programs are structured public health initiatives designed to systematically administer vaccines to populations, aiming to prevent the spread of infectious diseases. The proliferation of vaccination programs is attributed to increasing awareness of preventive healthcare, motivating more individuals to get vaccinated to avoid illnesses. Such programs improve the adoption of shingles vaccines by elevating public awareness and accessibility, making them particularly suitable for older adults and high-risk demographics. They also reduce the incidence of shingles and its associated complications through the promotion of timely and widespread immunization, thereby improving overall community health. For instance, in July 2025, the World Health Organization, a Switzerland-based Intergovernmental organization, noted that the coverage for the first dose of human papillomavirus (HPV) vaccine in girls climbed from 27% in 2023 to 31% in 2024. Thus, the rising volume of vaccination programs is a significant factor driving the growth of the shingles vaccine market.

How Is The Shingles Vaccine Market Broken Down By Segment Categories?

The shingles vaccine market covered in this report is segmented –

1) By Vaccine Type: Live Attenuated Vaccine, Recombinant Vaccine, Subunit Vaccine

2) By Product: Shingrix, Zostavax, Skyzoster

3) By Age Group: 50-59 Years, 60-69 Years, 70 Years And Above

4) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies

5) By End User: Hospitals, Clinics, Pharmacies

Subsegments:

1) By Live Attenuated Vaccine: Virus Strain A, Virus Strain B, Virus Strain C

2) By Recombinant Vaccine: Recombinant Protein Vaccine, Recombinant Vector Vaccine, Recombinant Deoxyribonucleic Acid Vaccine

3) By Subunit Vaccine: Protein Subunit Vaccine, Conjugate Subunit Vaccine

Which Trends Are Contributing To Changes In The Shingles Vaccine Market?

Leading companies active in the shingles vaccine market are concentrating on developing innovative vaccine formulations, such as recombinant adjuvanted vaccines, to bolster immune response and ensure long-lasting protection against shingles. These recombinant adjuvanted vaccines utilize lab-made viral proteins in conjunction with substances known as adjuvants to enhance the body’s immune response for improved and more enduring protection. For instance, in April 2023, GlaxoSmithKline Pharmaceuticals Ltd., an India-based pharmaceutical company, introduced Shingrix, a shingles vaccine. Shingrix is a non-live, recombinant adjuvanted subunit vaccine administered intramuscularly in two doses for adults aged 50 and above, specifically designed to prevent shingles (herpes zoster) and its related complication, post-herpetic neuralgia. This highly effective vaccine provides over 90% protection against shingles, establishing strong and sustained immunity that lasts at least 10 years, even in older adults and immunocompromised individuals.

Which Players Are Present In The Shingles Vaccine Market Space?

Major companies operating in the shingles vaccine market are Merck & Co. Inc., GSK plc, SK bioscience, Pfizer Inc, GeneOne Life Science, Curevo Inc, Novavax Inc

Get The Full Shingles Vaccine Market Report:

https://www.thebusinessresearchcompany.com/report/shingles-vaccine-global-market-report

Which Region Accounts For The Largest Portion Of The Shingles Vaccine Market?

North America was the largest region in the shingles vaccine market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the shingles vaccine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Shingles Vaccine Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/shingles-vaccine-global-market-report

Browse Through More Reports Similar to the Global Shingles Vaccine Market 2026, By The Business Research Company

Construction Market Report 2026

https://www.thebusinessresearchcompany.com/report/construction-global-market-report

Folding Furniture Market Report 2026

https://www.thebusinessresearchcompany.com/report/folding-furniture-global-market-report

Foldable Houses Market Report 2026

https://www.thebusinessresearchcompany.com/report/foldable-houses-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Is The Estimated Market Size Of The Shingles Vaccine Market In 2026, And How Will Its Value Evolve By 2030?

The shingles vaccine market size has witnessed rapid growth in recent years. It is anticipated to increase from $5.55 billion in 2025 to $6.37 billion in 2026, driven by a compound annual growth rate (CAGR) of 14.8%. Historically, this expansion has been primarily due to factors such as the limited availability of shingles vaccines, the reliance on live attenuated vaccines, a growing elderly population, the increasing incidence of herpes zoster, and a rising awareness of the benefits of immunization.

The shingles vaccine market is projected to experience substantial expansion in the coming years, with expectations to reach $10.96 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 14.5%. This projected increase is primarily driven by the advancement of recombinant and subunit vaccines, the broadening scope of public and private vaccination efforts, the growing preference for online and retail pharmacy distribution channels, intensified government and healthcare initiatives to immunize the elderly, and the incorporation of digital health monitoring to ensure vaccination compliance. Key developments expected during this period involve a surge in the uptake of recombinant and subunit shingles vaccines, heightened public awareness regarding shingles prevention among older adults, an increase in vaccination program availability through hospitals and retail pharmacies, the expansion of online pharmacies and e-commerce for vaccine distribution, and a strategic emphasis on immunization plans tailored for the population aged 50 and above.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=27413&type=smp

Which Drivers Are Supporting The Shingles Vaccine Market Growth?

A growing number of vaccination programs is anticipated to propel the expansion of the shingles vaccine market in the future. These programs are structured public health initiatives designed to systematically administer vaccines to populations, aiming to prevent the spread of infectious diseases. The proliferation of vaccination programs is attributed to increasing awareness of preventive healthcare, motivating more individuals to get vaccinated to avoid illnesses. Such programs improve the adoption of shingles vaccines by elevating public awareness and accessibility, making them particularly suitable for older adults and high-risk demographics. They also reduce the incidence of shingles and its associated complications through the promotion of timely and widespread immunization, thereby improving overall community health. For instance, in July 2025, the World Health Organization, a Switzerland-based Intergovernmental organization, noted that the coverage for the first dose of human papillomavirus (HPV) vaccine in girls climbed from 27% in 2023 to 31% in 2024. Thus, the rising volume of vaccination programs is a significant factor driving the growth of the shingles vaccine market.

How Is The Shingles Vaccine Market Broken Down By Segment Categories?

The shingles vaccine market covered in this report is segmented –

1) By Vaccine Type: Live Attenuated Vaccine, Recombinant Vaccine, Subunit Vaccine

2) By Product: Shingrix, Zostavax, Skyzoster

3) By Age Group: 50-59 Years, 60-69 Years, 70 Years And Above

4) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies

5) By End User: Hospitals, Clinics, Pharmacies

Subsegments:

1) By Live Attenuated Vaccine: Virus Strain A, Virus Strain B, Virus Strain C

2) By Recombinant Vaccine: Recombinant Protein Vaccine, Recombinant Vector Vaccine, Recombinant Deoxyribonucleic Acid Vaccine

3) By Subunit Vaccine: Protein Subunit Vaccine, Conjugate Subunit Vaccine

Which Trends Are Contributing To Changes In The Shingles Vaccine Market?

Leading companies active in the shingles vaccine market are concentrating on developing innovative vaccine formulations, such as recombinant adjuvanted vaccines, to bolster immune response and ensure long-lasting protection against shingles. These recombinant adjuvanted vaccines utilize lab-made viral proteins in conjunction with substances known as adjuvants to enhance the body’s immune response for improved and more enduring protection. For instance, in April 2023, GlaxoSmithKline Pharmaceuticals Ltd., an India-based pharmaceutical company, introduced Shingrix, a shingles vaccine. Shingrix is a non-live, recombinant adjuvanted subunit vaccine administered intramuscularly in two doses for adults aged 50 and above, specifically designed to prevent shingles (herpes zoster) and its related complication, post-herpetic neuralgia. This highly effective vaccine provides over 90% protection against shingles, establishing strong and sustained immunity that lasts at least 10 years, even in older adults and immunocompromised individuals.

Which Players Are Present In The Shingles Vaccine Market Space?

Major companies operating in the shingles vaccine market are Merck & Co. Inc., GSK plc, SK bioscience, Pfizer Inc, GeneOne Life Science, Curevo Inc, Novavax Inc

Get The Full Shingles Vaccine Market Report:

https://www.thebusinessresearchcompany.com/report/shingles-vaccine-global-market-report

Which Region Accounts For The Largest Portion Of The Shingles Vaccine Market?

North America was the largest region in the shingles vaccine market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the shingles vaccine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Shingles Vaccine Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/shingles-vaccine-global-market-report

Browse Through More Reports Similar to the Global Shingles Vaccine Market 2026, By The Business Research Company

Construction Market Report 2026

https://www.thebusinessresearchcompany.com/report/construction-global-market-report

Folding Furniture Market Report 2026

https://www.thebusinessresearchcompany.com/report/folding-furniture-global-market-report

Foldable Houses Market Report 2026

https://www.thebusinessresearchcompany.com/report/foldable-houses-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Size Expansion Is Predicted For The Shingles Vaccine Market Between 2026 And 2030?

The shingles vaccine market has experienced substantial expansion in recent years. Projections indicate its value will increase from $5.55 billion in 2025 to $6.37 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 14.8%. Factors contributing to this historical growth include the initial limited availability of shingles vaccines, a past reliance on live attenuated vaccines, an expanding elderly demographic, a higher incidence of herpes zoster, and heightened awareness regarding the advantages of immunization.

The shingles vaccine market is projected for significant expansion in the coming years, anticipated to reach $10.96 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 14.5%. This growth during the forecast period is propelled by factors such as the advancement of recombinant and subunit vaccines, the broadening scope of public and private vaccination efforts, wider use of online and retail pharmacy channels for distribution, escalating government and healthcare programs promoting immunization for seniors, and the incorporation of digital health monitoring to ensure vaccination adherence. Key trends expected over the forecast horizon encompass the growing embrace of recombinant and subunit shingles vaccines, heightened awareness regarding shingles prevention among the elderly, the proliferation of vaccination initiatives via hospitals and retail pharmacies, the expansion of online pharmacies and e-commerce for vaccine distribution, and a concentrated effort on age-specific immunization approaches targeting the 50+ demographic.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=27413&type=smp

Which Growth Drivers Are Contributing To The Progress Of The Shingles Vaccine Market?

A rising trend in vaccination initiatives is anticipated to stimulate the expansion of the shingles vaccine market in the future. These programs are structured public health efforts aimed at systematically delivering vaccines to communities to curb the dissemination of contagious illnesses. The proliferation of such programs stems from heightened public understanding of preventive healthcare, motivating individuals to seek vaccination for disease prevention. Through boosting public consciousness and improving access, these initiatives improve the uptake of the shingles vaccine, proving particularly beneficial for seniors and vulnerable groups. By facilitating prompt and broad immunization, they mitigate the danger of shingles and its associated complications, thus enhancing collective public health. For example, data from July 2025, provided by the World Health Organization, a Switzerland-based Intergovernmental organization, indicates that the coverage for the initial dose of the human papillomavirus (HPV) vaccine among girls rose from 27% in 2023 to 31% in 2024. Consequently, the expanding volume of vaccination initiatives is fueling the advancement of the shingles vaccine market.

Which Market Segments Are Examined In The Shingles Vaccine Market Study?

The shingles vaccine market covered in this report is segmented –

1) By Vaccine Type: Live Attenuated Vaccine, Recombinant Vaccine, Subunit Vaccine

2) By Product: Shingrix, Zostavax, Skyzoster

3) By Age Group: 50-59 Years, 60-69 Years, 70 Years And Above

4) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies

5) By End User: Hospitals, Clinics, Pharmacies

Subsegments:

1) By Live Attenuated Vaccine: Virus Strain A, Virus Strain B, Virus Strain C

2) By Recombinant Vaccine: Recombinant Protein Vaccine, Recombinant Vector Vaccine, Recombinant Deoxyribonucleic Acid Vaccine

3) By Subunit Vaccine: Protein Subunit Vaccine, Conjugate Subunit Vaccine

Which Trends Are Influencing The Shingles Vaccine Market?

Key companies operating in the shingles vaccine market are concentrating on developing innovative vaccine formulations, notably recombinant adjuvanted vaccines, to enhance immune response and provide long-lasting protection against shingles. Recombinant adjuvanted vaccines utilize laboratory-made viral proteins combined with substances known as adjuvants to bolster the body’s immune response for improved and extended protection. For instance, in April 2023, GlaxoSmithKline Pharmaceuticals Ltd., an India-based pharmaceutical company, launched its shingles vaccine, Shingrix. Shingrix is an inactivated, recombinant adjuvanted subunit vaccine administered intramuscularly in two doses for individuals aged 50 and above, aimed at preventing shingles (herpes zoster) and its related complication, post-herpetic neuralgia. This highly effective vaccine delivers over 90% protection against shingles, ensuring strong and sustained immunity for at least 10 years, even in older adults and immunocompromised individuals.

Who Are The Primary Competitors In The Shingles Vaccine Market?

Major companies operating in the shingles vaccine market are Merck & Co. Inc., GSK plc, SK bioscience, Pfizer Inc, GeneOne Life Science, Curevo Inc, Novavax Inc

Read the full shingles vaccine market report here:

https://www.thebusinessresearchcompany.com/report/shingles-vaccine-global-market-report

What Are The Leading Geographic Regions In The Shingles Vaccine Market?

North America was the largest region in the shingles vaccine market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the shingles vaccine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Shingles Vaccine Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=27413&type=smp

Browse Through More Reports Similar to the Global Shingles Vaccine Market 2026, By The Business Research Company

Construction Market Report 2026

https://www.thebusinessresearchcompany.com/report/construction-global-market-report

Folding Furniture Market Report 2026

https://www.thebusinessresearchcompany.com/report/folding-furniture-global-market-report

Foldable Houses Market Report 2026

https://www.thebusinessresearchcompany.com/report/foldable-houses-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the shingles vaccine market from 2026–2035 with trusted insights from The Business Research Company

What long-term size projections exist for the Shingles Vaccine Market covering 2026–2035?

The shingles vaccine market has experienced rapid expansion in recent years. It is projected to grow from $5.55 billion in 2025 to $6.37 billion in 2026, driven by a compound annual growth rate (CAGR) of 14.8%. This market’s historical growth can be attributed to factors such as the limited availability of shingles vaccines, a reliance on live attenuated vaccines, a growing elderly population, an increasing incidence of herpes zoster, and rising awareness regarding the benefits of immunization.

The shingles vaccine market size is projected for substantial expansion in the coming years. It is forecast to achieve $10.96 billion by 2030, progressing at a compound annual growth rate (CAGR) of 14.5%. This growth over the forecast period stems from various factors, including the advancement of recombinant and subunit vaccines, the broadening of public and private vaccination efforts, increased uptake of online and retail pharmacy distribution channels, intensified government and healthcare initiatives aimed at elderly immunization, and the integration of digital health monitoring to support vaccination adherence. Significant trends anticipated during this period involve the rising adoption of recombinant and subunit shingles vaccines, enhanced awareness among older adults regarding shingles prevention, the expansion of vaccination programs through hospital and retail pharmacies, the development of online pharmacies and e-commerce for vaccine distribution, and a concentrated focus on age-specific immunization strategies for the 50+ population.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=27413&type=smp

Which Drivers Are Impacting The Competitive Landscape Of The Shingles Vaccine Market?

A rise in vaccination programs is anticipated to fuel expansion within the shingles vaccine market in the future. These programs are structured public health efforts focused on systematically delivering vaccines to populations to curb the spread of infectious illnesses. The surge in vaccination programs stems from heightened awareness of preventative health measures, motivating a greater number of individuals to seek immunization against diseases. They boost the uptake of the shingles vaccine by improving public understanding and availability, rendering them particularly suitable for older adults and demographics at higher risk. Such programs mitigate the likelihood of shingles and its associated complications through encouraging prompt and extensive immunization, thereby enhancing general community well-being. As an illustration, in July 2025, the World Health Organization, an intergovernmental body situated in Switzerland, reported that the coverage for the initial dose of the human papillomavirus (HPV) vaccine among girls rose from 27% in 2023 to 31% in 2024. Consequently, the expanding quantity of vaccination programs is propelling the advancement of the shingles vaccine market.

What Segments Are Identified Within The Structure Of The Shingles Vaccine Market?

The shingles vaccine market covered in this report is segmented –

1) By Vaccine Type: Live Attenuated Vaccine, Recombinant Vaccine, Subunit Vaccine

2) By Product: Shingrix, Zostavax, Skyzoster

3) By Age Group: 50-59 Years, 60-69 Years, 70 Years And Above

4) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies

5) By End User: Hospitals, Clinics, Pharmacies

Subsegments:

1) By Live Attenuated Vaccine: Virus Strain A, Virus Strain B, Virus Strain C

2) By Recombinant Vaccine: Recombinant Protein Vaccine, Recombinant Vector Vaccine, Recombinant Deoxyribonucleic Acid Vaccine

3) By Subunit Vaccine: Protein Subunit Vaccine, Conjugate Subunit Vaccine

Which Trends Are Shaping Activity Within The Shingles Vaccine Market?

Leading companies in the shingles vaccine market are concentrating on developing innovative vaccine formulations, such as recombinant adjuvanted vaccines, to strengthen immune response and offer prolonged protection against shingles. Recombinant adjuvanted vaccines incorporate laboratory-produced viral proteins alongside substances called adjuvants to amplify the body’s immune reaction for more effective and enduring safeguarding. For instance, in April 2023, GlaxoSmithKline Pharmaceuticals Ltd., an India-based pharmaceutical company, launched Shingrix, a shingles vaccine. Shingrix is a non-live, recombinant adjuvanted subunit vaccine administered intramuscularly in two doses for adults aged 50 and above, specifically designed to prevent shingles (herpes zoster) and its related complication, post-herpetic neuralgia. This highly effective vaccine provides over 90% protection against shingles, with robust and sustained immunity lasting at least 10 years, even in older adults and immunocompromised individuals.

Which Key Players Are Driving Competition In The Shingles Vaccine Market?

Major companies operating in the shingles vaccine market are Merck & Co. Inc., GSK plc, SK bioscience, Pfizer Inc, GeneOne Life Science, Curevo Inc, Novavax Inc

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/shingles-vaccine-global-market-report

Which Region Is Projected To Lead The Shingles Vaccine Market During The Forecast Period?

North America was the largest region in the shingles vaccine market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the shingles vaccine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Shingles Vaccine Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=27413&type=smp

Browse Through More Reports Similar to the Global Shingles Vaccine Market 2026, By The Business Research Company

Construction Market Report 2026

https://www.thebusinessresearchcompany.com/report/construction-global-market-report

Folding Furniture Market Report 2026

https://www.thebusinessresearchcompany.com/report/folding-furniture-global-market-report

Foldable Houses Market Report 2026

https://www.thebusinessresearchcompany.com/report/foldable-houses-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the shingles vaccine market from 2025–2034 with trusted insights from The Business Research Company

What Is The Predicted Market Size Of The Shingles Vaccine Industry By 2029?

The shingles vaccine market has seen substantial growth over recent years. It is anticipated to expand from $4.82 billion in 2024 to $5.55 billion in 2025, achieving a compound annual growth rate (CAGR) of 15.0%. This historical expansion is largely due to factors such as an expanding elderly demographic, increased public understanding of vaccine advantages, improvements in healthcare infrastructure and immunization schemes, a greater occurrence of immunocompromised states, and the growing acceptance of advanced, more potent vaccines.

The shingles vaccine market size is anticipated to undergo rapid expansion in the upcoming years, projected to reach $9.58 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 14.6%. This growth during the forecast period is primarily driven by factors such as expanding government reimbursement and beneficial pricing policies, a rise in physician recommendation rates, an increased public health focus on adult vaccination, growing investments in research and development along with product diversification, and improvements in global supply chains and cold-chain capacity. Significant trends expected during this period include advances in recombinant vaccine technology, enhancements in adjuvant systems, the integration of shingles vaccination into standard adult immunization schedules, the adoption of digital health platforms for tracking vaccines, and progress in vaccine formulations.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=27413&type=smp

Which Factors Are Steering Growth In The Shingles Vaccine Market?

The expanding presence of vaccination initiatives is projected to boost the future expansion of the shingles vaccine market. These initiatives are structured public health efforts aimed at systematically delivering vaccines to communities to prevent the spread of infectious diseases. The rise in vaccination programs is driven by heightened consciousness regarding preventive healthcare, prompting more individuals to seek vaccination for disease prevention. Vaccination programs boost the uptake of shingles vaccines by improving public understanding and availability, making them suitable for older adults and at-risk demographics. They mitigate the danger of shingles and its associated complications through encouraging prompt and extensive immunization, thereby enhancing overall public well-being. For example, in July 2025, the World Health Organization, a Switzerland-based Intergovernmental organization, reported that the coverage for the first dose of human papillomavirus (HPV) vaccine in girls rose from 27% in 2023 to 31% in 2024. Consequently, the growing prevalence of vaccination programs is fueling the growth of the shingles vaccine market.

Which Segment Accounts For The Largest Share In The Shingles Vaccine Market?

The shingles vaccine market covered in this report is segmented

1) By Vaccine Type: Live Attenuated Vaccine, Recombinant Vaccine, Subunit Vaccine

2) By Product: Shingrix, Zostavax, Skyzoster

3) By Age Group: 50-59 Years, 60-69 Years, 70 Years And Above

4) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies

5) By End User: Hospitals, Clinics, Pharmacies

Subsegments:

1) By Live Attenuated Vaccine: Virus Strain A, Virus Strain B, Virus Strain C

2) By Recombinant Vaccine: Recombinant Protein Vaccine, Recombinant Vector Vaccine, Recombinant Deoxyribonucleic Acid Vaccine

3) By Subunit Vaccine: Protein Subunit Vaccine, Polysaccharide Subunit Vaccine, Conjugate Subunit Vaccine

Which Long-Term Trends Will Play A Crucial Role In The Shingles Vaccine Market?

Key companies within the shingles vaccine market are prioritizing the development of advanced vaccine formulations, such as recombinant adjuvanted vaccines, to bolster immune responses and deliver enduring protection against shingles. Recombinant adjuvanted vaccines work by combining laboratory-engineered viral proteins with substances known as adjuvants, which serve to intensify the body’s immune defense for superior and longer-lasting immunity. As an illustration, in April 2023, GlaxoSmithKline Pharmaceuticals Ltd., an India-based pharmaceutical company, launched Shingrix, a vaccine specifically for shingles. Shingrix is a non-live, recombinant adjuvanted subunit vaccine given intramuscularly in two doses to adults aged 50 and above, designed to avert shingles (herpes zoster) and its related severe condition, post-herpetic neuralgia. This highly potent vaccine provides over 90% protection against shingles, ensuring a strong and sustained immunity that persists for at least 10 years, even among older adults and those with compromised immune systems.

Who Are The Dominant Players In The Shingles Vaccine Market Today?

Major companies operating in the shingles vaccine market are Pfizer Inc., Merck & Co. Inc., Sanofi S.A., GSK plc, Daiichi Sankyo Company Limited, Moderna Inc., Novavax Inc., Biological E. Limited., Serum Institute of India Pvt. Ltd., Dynavax Technologies Corporation, SK Bioscience Co. Ltd., CanSino Biologics Inc., Vaxart Inc., EuBiologics Co. Ltd., BCHT Biotech Co. Ltd., Green Cross Corp, Jiangsu Recbio Technology Co. Ltd., Curevo Inc., Inovio Pharmaceuticals Inc., POP Biotechnologies Inc.

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/shingles-vaccine-global-market-report

What Regional Factors Are Accelerating Growth In The Shingles Vaccine Market?

North America was the largest region in the shingles vaccine market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the shingles vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=27413&type=smp

Browse Through More Reports Similar to the Global Shingles Vaccine Market 2025, By The Business Research Company

Construction Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/construction-global-market-report

Foldable Houses Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/foldable-houses-global-market-report

Excavation And Demolition Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/excavation-and-demolition-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Is The Global Market Value Of The Shingles Vaccine Industry In 2025?

The market for the shingles vaccine has experienced swift expansion over recent years. This market is projected to expand from $4.82 billion in 2024 to $5.55 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 15.0%. Historically, this expansion has stemmed from factors such as an expanding older demographic, heightened understanding of the advantages of vaccination, improvements in healthcare infrastructure alongside robust immunization initiatives, a greater occurrence of immunocompromised states, and the increased uptake of advanced, more efficacious vaccines.

The shingles vaccine market size is anticipated to experience significant expansion in the coming years, projected to reach $9.58 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 14.6%. This growth during the forecast period is fueled by several factors, including increasing government reimbursement and beneficial pricing policies, a rise in physician recommendations, heightened public health emphasis on adult vaccination, greater investment in research and development alongside product diversification, and improvements in global supply chains and cold-chain capacity. Prominent trends within this period are expected to include advancements in recombinant vaccine technology, progress in adjuvant systems, the integration of shingles vaccination into adult immunization schedules, the incorporation of digital health platforms for vaccine tracking, and innovations in vaccine formulations.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=27413&type=smp

What Are The Key Drivers Of Growth In The Shingles Vaccine Market?

A growing number of vaccination initiatives is projected to fuel the expansion of the shingles vaccine market moving forward. These programs are organized public health endeavors designed to systematically administer vaccines to populations to avert the spread of infectious diseases. The increase in vaccination programs stems from greater awareness regarding preventive healthcare, prompting more individuals to seek immunization to avoid illnesses. Vaccination programs boost shingles vaccine adoption by improving public awareness and access, making them highly beneficial for older adults and at-risk groups. They diminish the likelihood of shingles and related complications through the promotion of timely and extensive immunization, thereby enhancing overall community health. For instance, in July 2025, according to the World Health Organization, a Switzerland-based Intergovernmental organization, the coverage for the first dose of human papillomavirus (HPV) vaccine in girls climbed from 27% in 2023 to 31% in 2024. Therefore, the rising incidence of vaccination programs is driving the growth of the shingles vaccine market.

What Are The Different Segment Classifications Within The Shingles Vaccine Market?

The shingles vaccine market covered in this report is segmented

1) By Vaccine Type: Live Attenuated Vaccine, Recombinant Vaccine, Subunit Vaccine

2) By Product: Shingrix, Zostavax, Skyzoster

3) By Age Group: 50-59 Years, 60-69 Years, 70 Years And Above

4) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies

5) By End User: Hospitals, Clinics, Pharmacies

Subsegments:

1) By Live Attenuated Vaccine: Virus Strain A, Virus Strain B, Virus Strain C

2) By Recombinant Vaccine: Recombinant Protein Vaccine, Recombinant Vector Vaccine, Recombinant Deoxyribonucleic Acid Vaccine

3) By Subunit Vaccine: Protein Subunit Vaccine, Polysaccharide Subunit Vaccine, Conjugate Subunit Vaccine

What Key Innovation Trends Are Fueling Advancements In The Shingles Vaccine Market?

Major companies operating in the shingles vaccine market are prioritizing the creation of innovative vaccine formulations, including recombinant adjuvanted vaccines, to improve immune response and offer long-lasting protection against shingles. Recombinant adjuvanted vaccines function by using laboratory-produced viral proteins alongside substances called adjuvants to amplify the body’s immune response for enhanced and more enduring protection. For instance, in April 2023, GlaxoSmithKline Pharmaceuticals Ltd., an India-based pharmaceutical company, introduced Shingrix, a shingles vaccine. Shingrix is a non-live, recombinant adjuvanted subunit vaccine administered intramuscularly in two doses for adults aged 50 and above, engineered to prevent shingles (herpes zoster) and its associated complication, post-herpetic neuralgia. This highly effective vaccine delivers over 90% protection against shingles, with robust and sustained immunity lasting a minimum of 10 years, even in older adults and individuals with compromised immune systems.

Which Major Industry Participants Are Leading The Shingles Vaccine Market Growth?

Major companies operating in the shingles vaccine market are Pfizer Inc., Merck & Co. Inc., Sanofi S.A., GSK plc, Daiichi Sankyo Company Limited, Moderna Inc., Novavax Inc., Biological E. Limited., Serum Institute of India Pvt. Ltd., Dynavax Technologies Corporation, SK Bioscience Co. Ltd., CanSino Biologics Inc., Vaxart Inc., EuBiologics Co. Ltd., BCHT Biotech Co. Ltd., Green Cross Corp, Jiangsu Recbio Technology Co. Ltd., Curevo Inc., Inovio Pharmaceuticals Inc., POP Biotechnologies Inc.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/shingles-vaccine-global-market-report

Which Region Is Projected To Lead The Shingles Vaccine Market During The Forecast Period?

North America was the largest region in the shingles vaccine market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the shingles vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Shingles Vaccine Market Report:

https://www.thebusinessresearchcompany.com/customise?id=27413&type=smp

Browse Through More Reports Similar to the Global Shingles Vaccine Market 2025, By The Business Research Company

Construction Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/construction-global-market-report

Folding Furniture Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/folding-furniture-global-market-report

Foldable Houses Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/foldable-houses-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model